The field of partial epigenetic reprogramming is accelerating.
The science of partial epigenetic reprogramming (transient OSK factors) has moved from theory to compelling preclinical results and even first human trials in just the last two years. Below are verified, publicly reported advances as of March 2026.
Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice
Macip et al.
Key Result: OSK delivered via AAV in 124-week-old mice extended median remaining lifespan by 109% and significantly improved frailty scores and multiple health parameters.
Targeted Partial Reprogramming of Age-Associated Cell States Improves Markers of Health
Sahu et al.
Key Result: Single AAV injection targeting senescent cells with OSK extended lifespan in progeroid mice (~40%) and naturally aged wild-type mice (~12%), reduced inflammation, restored tissue integrity, and enhanced wound healing.
The Long and Winding Road of Reprogramming-Induced Rejuvenation
Yücel et al. (review)
Key Result: Comprehensive analysis showing partial reprogramming reverses epigenetic clocks, improves tissue function across multiple organs, and extends lifespan in aged models.
Chemical-Induced Partial Reprogramming Ameliorates Cellular Hallmarks of Aging
Schoenfeldt et al.
Key Result: Optimized two-chemical cocktail restored youthful transcript profiles, reduced genomic instability, senescence, and ROS in aged human cells; extended lifespan in model organisms.
First Human Trial Clearance for Partial Epigenetic Reprogramming
Life Biosciences (ER-100)
Key Result: FDA cleared Phase 1 trial for optic neuropathies (glaucoma/NAION) using partial reprogramming gene therapy — the first-ever human test of the approach. Trial enrollment began 2026.
Cognitive Rejuvenation Through Partial Reprogramming of Engram Cells
(Neuron journal study)
Key Result: OSK reprogramming of memory-encoding neurons in aged and Alzheimer's-model mice restored youthful gene expression, synaptic plasticity, and learning/memory performance to young-animal levels.
YouthBio Therapeutics – Neuron-Specific Partial Reprogramming
Positive FDA feedback for brain-targeted therapy
Key Result: Preclinical data showed cognitive improvement in aged mice without affecting young animals.
The Momentum is Real
These independent advances — from university labs to well-funded biotechs — show the field is gaining real traction. Researchers worldwide are publishing faster; investors are allocating billions; regulators are now approving early human studies.
EpochRevive, initiated by Mahboob Hasan (Founder & CEO, Cosmyra Technologies Private Limited), follows this momentum closely and is exploring safe, responsible ways to contribute. We welcome collaboration from scientists and thoughtful investors who share the vision.
EpochRevive tracks these advances and aims to contribute responsibly in the future. No proprietary data or trials yet.